A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Completed · Phase 3 · Has a placebo group

Conditions studied: Heart Failure With Preserved Ejection Fraction

In brief

The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).

Key facts

Study ID

NCT03066804

Run by

Novartis Pharmaceuticals

People needed

2572

Starts

2017-08-22

Expected to finish

2019-10-28

Last updated by the study team

2021-10-11

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Left ventricular ejection fraction (LVEF) >40% by echo within 6 months prior to study entry or during the screening epoch
• Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop, or thiazide diuretics, or mineralocorticoid antagonist [MRAs]) for at least 30 days prior to study entry
• NYHA class II-IV
• Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.
• NT-proBNP > 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or >600 pg/mL for patients with AF
• KCCQ clinical summary score < 75
• Patients on ACEi or ARB therapy must have a history of HTN

You may not qualify if…

• Any prior measurement of LVEF ≤ 40%, under stable conditions
• Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention (PCI) within 3 months or an elective PCI within 30 days prior to study entry
• Any clinical event within the 6 months prior to Visit 1 that could have reduced the LVEF (eg MI, coronary artery bypass graft [CABG]), unless an echo measurement was performed after the event confirming the LVEF to be >40%
• Current (within 30 days from Visit 1) acute decompensated HF requiring therapy.
• Current (within 30 days from Visit 1) use of renin inhibitor(s), dual RAS blockade or LCZ696
• History of hypersensitivity to LCZ696 or its components
• Patients with a known history of angioedema
• Walk distance primarily limited by non-cardiac comorbid conditions at study entry
• Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) <10 g/dL males and < 9.5 g/dL females, or body mass index (BMI) > 40 kg/m\^2.
• Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP >150 mmHg and <180 mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP < 110 mmHg at study entry.
• Patients with HbA1c > 7.5% not treated for diabetes
• Patients with prior major organ transplant or intent to transplant (ie on transplant list)
• eGFR < 30 ml/min/1.73 m\^2 as measured by MDRD at screening
• Serum potassium > 5.2 mmol /L (or equivalent plasma potassium value) at study entry
• History or presence of any other disease with a life expectancy of < 3 years
• Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigative Site — Mobile, Alabama, United States
• Novartis Investigative Site — Beverly Hills, California, United States
• Novartis Investigative Site — Long Beach, California, United States
• Novartis Investigative Site — Santa Ana, California, United States
• Novartis Investigative Site — Sylmar, California, United States
• Novartis Investigative Site — Aurora, Colorado, United States
• Novartis Investigative Site — Stamford, Connecticut, United States
• Novartis Investigative Site — Bradenton, Florida, United States
• Novartis Investigative Site — Gainesville, Florida, United States
• Novartis Investigative Site — Hollywood, Florida, United States
• Novartis Investigative Site — Miami, Florida, United States
• Novartis Investigative Site — Port Orange, Florida, United States
• Novartis Investigative Site — Thomasville, Georgia, United States
• Novartis Investigative Site — Arlington Heights, Illinois, United States
• Novartis Investigative Site — Alexandria, Louisiana, United States
• Novartis Investigative Site — Chalmette, Louisiana, United States
• Novartis Investigative Site — Houma, Louisiana, United States
• Novartis Investigative Site — Boston, Massachusetts, United States
• Novartis Investigative Site — Lincoln, Nebraska, United States
• Novartis Investigative Site — Omaha, Nebraska, United States
• Novartis Investigative Site — Rochester, New York, United States
• Novartis Investigative Site — Marion, Ohio, United States
• Novartis Investigative Site — Corvallis, Oregon, United States
• Novartis Investigative Site — Abington, Pennsylvania, United States
• Novartis Investigative Site — Andalusia, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.